Stocksigma LogoStocksigma Logo

Granules India Submits Paragraph IV ANDA for Ruxolitinib Extended-Release Tablets

Granules India Limited announced on 7th Oct'26 that it has submitted a Paragraph IV certification with its Abbreviated New Drug Application (ANDA) for

Granules India Submits Paragraph IV ANDA for Ruxolitinib Extended-Release Tablets

Granules India Ltd 路 Press Release 路 07 Oct 2026, 6:10 pm

Granules India Submits Paragraph IV ANDA for Ruxolitinib Extended-Release Tablets Granules India Limited announced on 7th Oct'26 that it has submitted a Paragraph IV certification with its Abbreviated New Drug Application (ANDA) for generic Ruxolitinib Extended-Release Tablets to the US FDA. Based on filing status and timing, the company believes it is eligible for first-to-file status, which, upon FDA confirmation and statutory approvals, could provide 180 days of generic drug marketing exclusivity under US law. The ANDA, exclusivity status, and commercialization prospects remain under regulatory review.

Original exchange filing (PDF)

More announcements from Granules India Ltd

All Granules India Ltd announcements